The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 2, 2012, Pages 555-562

  Shapiro, Geoffrey I ^a   Frank, Richard ^b   Dandamudi, Uday B ^c   Hengelage, Thomas ^d   Zhao, Lily ^d   Gazi, Lucien ^d   Porro, Maria Grazia ^d   Woo, Margaret M ^d   Lewis, Lionel D ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NORWALK HOSPITAL   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Food; Histone deacetylase inhibitor; Panobinostat; Pharmacokinetics

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; PANOBINOSTAT;

ABDOMINAL PAIN; ADENOID CYSTIC CARCINOMA; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COLON CANCER; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DIARRHEA; DIET RESTRICTION; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FEVER; FOOD DRUG INTERACTION; FOOD INTAKE; HEAD AND NECK CANCER; HEADACHE; HUMAN; HYPOKALEMIA; INSOMNIA; KIDNEY CARCINOMA; LIPID DIET; LUNG CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROENDOCRINE TUMOR; OVARY CANCER; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROSTATE CANCER; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOFT TISSUE SARCOMA; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THYROID CANCER; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DIET, HIGH-FAT; DRUG ADMINISTRATION SCHEDULE; EATING; FASTING; FATIGUE; FEMALE; FOOD; FOOD-DRUG INTERACTIONS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NAUSEA; NEOPLASMS; TREATMENT OUTCOME; VOMITING;

EID: 84856749798     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1758-x     Document Type: Article

References (21)

1. JE Bolden MJ Peart RW Johnstone 2006 Anticancer activities of histone deacetylase inhibitors Nat Rev Drug Discov 5 769 784 16955068 10.1038/nrd2133 1:CAS:528:DC%2BD28XptVCltrY%3D (Pubitemid 44348499)
2. P Atadja 2009 Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges Cancer Lett 280 233 241 19344997 10.1016/j.canlet. 2009.02.019 1:CAS:528:DC%2BD1MXmsF2jtL4%3D
3. HM Prince MJ Bishton RW Johnstone 2009 Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors Future Oncol 5 601 612 19519200 10.2217/fon.09.36 1:CAS:528: DC%2BD1MXnt1GjtrY%3D
4. L Catley E Weisberg T Kiziltepe YT Tai T Hideshima P Neri P Tassone P Atadja D Chauhan NC Munshi KC Anderson 2006 Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells Blood 108 3441 3449 16728695 10.1182/blood-2006-04-016055 1:CAS:528:DC%2BD28Xht1ahsLzM
5. EM Ocio D Vilanova P Atadja P Maiso E Crusoe D Fernandez-Lazaro M Garayoa L San-Segundo T Hernandez-Iglesias E de Alava W Shao YM Yao A Pandiella JF San-Miguel 2010 In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma Haematologica 95 794 803 19951978 10.3324/haematol.2009. 015495 1:CAS:528:DC%2BC3cXht1yrsbzP
6. P Maiso E Colado EM Ocio M Garayoa J Martin P Atadja A Pandiella JF San-Miguel 2009 The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair Leukemia 23 2265 2274 19812608 10.1038/leu.2009.182 1:CAS:528:DC%2BD1MXhsFKns7bJ
7. M Lemoine D Buglio A Jona E Derenzini LJ Medeiros DA Berry A Younes 2010 The pan-deacetylase inhibitor panobinostat downregulates HIF-1{alpha} and VEGF and, synergizes with everolimus in Hodgkin lymphoma cell lines [abstract] Blood 116 2851 10.1182/blood-2010-02-268623
8. DS Welsbie J Xu Y Chen L Borsu HI Scher N Rosen CL Sawyers 2009 Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer Cancer Res 69 958 966 19176386 10.1158/0008-5472.CAN-08-2216 1:CAS:528:DC%2BD1MXhtFOkur0%3D
9. R Rao S Nalluri R Kolhe Y Yang W Fiskus J Chen K Ha KM Buckley R Balusu V Coothankandaswamy A Joshi P Atadja KN Bhalla 2010 Treatment with panobinostat induces glucose-regulated protein 78 acetylation and endoplasmic reticulum stress in breast cancer cells Mol Cancer Ther 9 942 952 20371724 10.1158/1535-7163.MCT-09-0988 1:CAS:528:DC%2BC3cXktlCqt7Y%3D
10. HM Prince MJ Bishton SJ Harrison 2009 Clinical studies of histone deacetylase inhibitors Clin Cancer Res 15 3958 3969 19509172 10.1158/1078-0432.CCR-08-2785 1:CAS:528:DC%2BD1MXntlOis78%3D
11. M Mateos A Spencer K Taylor S Lonial J De La Rubia T Facon B Bengoudifa K Hazell PM Bourquelot JF San-Miguel 2010 Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM) [abstract] J Clin Oncol 28 15S 8030
12. JF San-Miguel PGG Richardson O Sezer A Guenther DSD Siegel J Blade R LeBlanc HJ Sutherland M Mateos M Gramatzki KM Hazell P Bengoudifa PM Bourquelot KC Anderson 2010 A phase lb study of oral panobinostat and IV bortezomib in relapsed or relapsed and refractory multiple myeloma J Clin Oncol 28 15S 8001
13. A Sureda A Younes D Ben-Yehuda T Ong JL Kaufman CL Le Corre J Gallagher A Shen A Engert 2010 Final analysis: phase II study of oral panobinostat in relapsed/refractory Hodgkin lymphoma patients following autologous hematopoietic stem cell transplant [abstract] Blood 116 419
14. JF San Miguel S Lonial V Hungria P Moreau H Einsele JH Lee S Yoon P Corradini WW Jedrzejczak DC Tan K Yong A Guenther MM Wroclawsk-Swacha HJ Weber PM Bourquelot PGG Richardson 2011 PANORAMA1: a randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma J Clin Oncol 29 15S TPS227
15. HM Prince D George A Patnaik M Mita M Dugan D Butterfoss E Masson KW Culver HA Burris III J Beck 2007 Phase I study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and non-Hodgkin's lymphoma [abstract] J Clin Oncol 25 18S 3500
16. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
17. HM Jones N Parrott G Ohlenbusch T Lave 2006 Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling Clin Pharmacokinet 45 1213 1226 17112297 10.2165/00003088-200645120- 00006 1:CAS:528:DC%2BD2sXnt1entQ%3D%3D (Pubitemid 44904824)
18. BN Singh BK Malhotra 2004 Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy Clin Pharmacokinet 43 1127 1156 15568891 10.2165/00003088-200443150-00005 1:CAS:528:DC%2BD2MXnvFSgsw%3D%3D (Pubitemid 40013180)
19. Woo MM, Culver K, Li W, Liu A, Scott J, Parker K, Jalaluddin M, Laird G, Cooper MR, Schran HF (2008) Panobinostat (LBH589) pharmacokinetics (PK): implication for clinical safety and efficacy [abstract]. Ann Oncol 19(suppl 8):viii161. Abstract 478P
20. GL Amidon H Lennernas VP Shah JR Crison 1995 A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm Res 12 413 420 7617530 10.1023/A:1016212804288 1:CAS:528:DyaK2MXksVGqur8%3D
21. EH Rubin NG Agrawal EJ Friedman P Scott KE Mazina L Sun L Du JL Ricker SR Frankel KM Gottesdiener JA Wagner M Iwamoto 2006 A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer Clin Cancer Res 12 7039 7045 17145826 10.1158/1078-0432.CCR-06-1802 1:CAS:528:DC%2BD28Xht1Kns7jF (Pubitemid 44974501)